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Abstract
Irradiation and DNA-damaging chemotherapeutic agents are commonly used in anticancer treatments. Following DNA
damage FOXM1 protein levels are often elevated. In this study, we sought to investigate the potential role of FOXM1 in
programmed cell death induced by DNA-damage. Human cancer cells after FOXM1 suppression were subjected to
doxorubicin or c-irradiation treatment. Our findings indicate that FOXM1 downregulation by stable or transient knockdown
using RNAi or by treatment with proteasome inhibitors that target FOXM1 strongly sensitized human cancer cells of
different origin to DNA-damage-induced apoptosis. We showed that FOXM1 suppresses the activation of pro-apoptotic JNK
and positively regulates anti-apoptotic Bcl-2, suggesting that JNK activation and Bcl-2 down-regulation could mediate
sensitivity to DNA-damaging agent-induced apoptosis after targeting FOXM1. Since FOXM1 is widely expressed in human
cancers, our data further support the fact that it is a valid target for combinatorial anticancer therapy.
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Introduction
c-irradiation and DNA-damaging chemotherapeutic drugs play
a key role in anticancer therapy due to their ability to induce DNA
double-strand breaks leading to cancer cell death [1]. Since cancer
cells often become resistant to DNA-damaging agents, it is
important to determine the mechanisms of drug-resistance.
Several studies have reported that in response to IR, etoposide,
daunorubicin or doxorubicin treatment FOXM1 protein level
increases in a dose-dependent manner [2–4]. FOXM1 is
considered to be a master regulator of the cell cycle [5,6] by
controlling the expression of genes that are crucial for G1/S and
G2/M progression [7]. FOXM1 is abundantly expressed in a wide
range of human cancers [8–11], suggesting that targeting FOXM1
could be a therapeutic strategy against human malignancies
[12,13]. FOXM1 has been implicated in the DNA-damage
response pathway, for example DNA repair genes, XRCC1 and
BRCA2 were identified as direct transcriptional targets of
FOXM1 [2]. In addition, the role of FOXM1 in response to
DNA-damage has been investigated in the context of human
cancer cells with wild type p53 [2,11,14,15]. However, tumor
suppressor p53 was found to be a negative regulator of FOXM1
and DNA-damage strongly upregulated the level of FOXM1 in
the absence of p53 [3,4]. Consequently, we hypothesized that
DNA-damaging chemotherapeutic agents may not be as efficient
in the absence of p53, as they stabilize FOXM1 protein level
leading to protection against DNA-damage-induced apoptosis.
Since FOXM1 is potentially an oncogenic transcription factor and
it is also involved in invasion and angiogenesis [16–24], treatment
of tumors where p53 is mutated or inactivated with DNA-
damaging agents could be detrimental for patients. Our group
reported previously that suppression of FOXM1 by thiazole
antibiotics [25–28] and by proteasome inhibitors [29] correlates
with the degree of apoptosis suggesting that FOXM1 may act as a
potential inhibitor of apoptosis [25–27]. Moreover, it has been
shown recently that breast cancer cells with elevated levels of
FOXM1 became insensitive to Herceptin, paclitaxel [30] and
cisplatin [11]. Therefore, it is evident that FOXM1 might inhibit
apoptosis induced by various anticancer drugs.
c-Jun N-terminal kinases (JNKs; also known as stress-activated
protein kinases, SAPKs) respond to diverse extracellular stimuli and
environmental stresses [31]. The JNK signaling pathway regulates
many cellular processes, such as proliferation, survival, apoptosis
and differentiation [32]. FOXM1 has been shown to transcription-
ally activate JNK1 to control cell cycle progression and invasion
[18]. However, the outcome of JNK activation is determined by the
duration of JNK signaling [33,34]. Short-term JNK activation is
linked to proliferation, while sustained activation of JNK usually
leads to apoptosis [33,34]. B-cell lymphoma 2 (Bcl-2) is an
antiapoptotic member of the Bcl-2 family [35,36]. Bcl-2 has a
centralrole inthe intrinsic apoptotic pathway actingas the guardian
of the mitochondria by inhibiting Bax activation [35,37]. Forced
overexpression of Bcl-2 in several cultured cell lines conferred
resistance to chemotherapeutic agents and irradiation [35].
In this study, we examined whether FOXM1 plays a role in cell
death induced by DNA-damage in human tumor cell lines with
mutant p53. We demonstrate that stable or transient knockdown
of FOXM1 using RNAi increases the sensitivity of different
human cancer cells to DNA-damaging agents including doxoru-
bicin treatment and c-irradiation. Moreover, we show that
combination of proteasome inhibitors that inhibit FOXM1 with
DNA-damaging agents induces very robust apoptosis. Our
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31761findings suggest that JNK activation and Bcl-2 downregulation
may account for the increased cell death after suppression of
FOXM1 in combination with DNA-damage.
Materials and Methods
Cell culture, chemical compounds and treatments
MIA PaCa-2 pancreatic (ATCC), Hep3B liver (ATCC), HCT
116 and HCT 116 shp53 colon [38] human cancer cell lines were
grown in DMEM medium (Invitrogen). MDA-MB-231 (ATCC)
breast human cancer cell line was grown in RPMI medium
(Invitrogen). The media were supplemented with 10% fetal bovine
serum (Atlanta Biologicals) and 1% penicillin-streptomycin
(GIBCO) and the cells were kept at 37uCi n5 %C O 2. Stable
cell lines (Fig. 1) using the ATCC obtained parental cells were
generated by transduction of control and FOXM1 shRNA
lentiviral particles (Sigma) followed by selection with puromycin
(Sigma). Doxorubicin (Fisher Scientific), thiostrepton (Sigma),
bortezomib (velcade) (Millenium Pharmaceuticals) and JNK
inhibitor SP600125 (A.G. Scientific) were dissolved in dimethyl
sulfoxide (Fisher Scientific). Irradiation was carried out using a
137Caesium c-source (J. L. Shepherd model 6810; J. L. Shepherd,
San Fernando, CA) at a dose of 8 and 10 Gy.
Immunoblot analysis
Treated cells were harvested and processed for immunoblotting
as described in ref. [27] with antibodies specific for FOXM1 (the
rabbit polyclonal antibody against FOXM1 was described
previously [45]), p53 (Santa Cruz), cleaved caspase-3 (Cell
signaling), PARP-1/2 (Santa Cruz), Total and Phospho-SAPK/
JNK (Cell signaling), Bcl-2 (Santa Cruz), Bcl-xL (Cell signaling)
and b-actin (Sigma). Quantification was done with the Image J
software (NIH). Relative protein levels were normalized to the
corresponding actin levels.
Transfection and siRNA
Control (AACAGUCGCGUUUGCGACUGGUU) small in-
terfering RNA (siRNA) and siRNA specific to FOXM1 (GGAC-
CACUUUCCCUACUUUUU) were synthesized by Sigma.
50 nM of siRNA duplexes were transfected into cells using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
recommendation. Cells were treated as indicated 48 hours after
transfection.
Total RNA extraction and Quantitative real-time
(qRT)-PCR
To extract total RNA cells were harvested by TRIzol reagent
(Invitrogen). cDNA was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Quanti-
tative real time PCR was run using the ABI 7900 HT (Applied
Biosystems) machine. The following primers were used: human
Bcl-2 (Sense, 59-TGG GAT GCC TTT GTG GAA CT-39;
Antisense, 59-GAG ACA GCC AGG AGA AAT CAA AC-39)
[46] and human cyclophilin (Sense, 59-GCA GAC AAG GTC
CCA AAG ACA G-39; Antisense, 59-CAC CCT GAC ACA TAA
ACC CTG G-39) [25].
Flow cytometry – Propidium Iodide staining
Cells were treated as indicated and harvested by trypsinization.
Then, cells were washed in PBS and fixed in ice-cold 95% ethanol.
Following fixation, cells were stained with propidium iodide
(50 mg/ml) (Invitrogen) in PBS/RNAse A/Triton X-100 for
30 min at room temperature and analyzed by flow cytometry.
Colony-forming assay
1610
5 cells were plated on 100 mm dishes in duplicates and
were treated as indicated for 24 hrs. Colonies were allowed to
form for 10 days, and then cells were stained with crystal violet.
Statistical analysis
Statistical analysis was performed with Microsoft Excel using
the Student t test (two-tailed). P values of ,0.05 were considered to
be statistically significant.
Results and Discussion
Knockdown of FOXM1 sensitizes human cancer cells to
DNA-damaging agents
First, isogenic HCT 116 p53 proficient and deficient human
colon cancer cells with FOXM1 knockdown were treated with
different concentrations of doxorubicin (Doxo) and cell death was
assessed by immunoblotting for markers of apoptosis including
cleaved caspase-3 and PARP (Fig. 1A). Knockdown of FOXM1
enhanced sensitivity of colon cancer cells to doxorubicin-mediated
apoptosis independently of p53 status. p53 proficient cells with
FOXM1 knockdown underwent stronger apoptosis compared to
their p53 deficient counterparts. This observation could be
explained by the presence of p53-dependent apoptotic signaling
in the p53-proficient cells, but not in the p53-deficient cells
following DNA-damage.
About 50% of human tumors harbor mutant or inactivated p53;
consequently the p53-dependent apoptotic pathway cannot be
exploited for the eradication of cancer cells following anticancer
treatment [39].To investigate the possible roleof FOXM1in DNA-
damage-induced apoptosis in cell lines with mutant p53, which are
usually more resistant to chemotherapy than cancer cell lines with
wild-type p53, MIA PaCa-2 vector control and FOXM1 knock-
down human pancreatic cancer cell lines harboring mutant p53
were treated with increasing concentrations of doxorubicin and
immunoblotting wasperformed forFOXM1,cleavedcaspase-3 and
PARP (Fig. 1B). In accordance with earlier studies [2–4,11,14,40],
we also observed that following DNA-damage FOXM1 protein
level iselevated.Butmoreimportantly,we found that theabsence of
FOXM1 sensitized cancer cells to cell death induced by
doxorubicin (Fig. 1B) as detected by the cleavage of caspase-3 and
PARP. To verify that this phenomenon is not cell line specific,
MDA-MB-231 human breast (p53-mutant) (Fig. 1C) and Hep3B
human liver (p53-null) (Fig. 1D) vector control and FOXM1
knockdown cancer cells were treated with different concentrations
of doxorubicin. Western blot analysis of cleaved caspase-3
demonstrated that knockdown of FOXM1 also sensitized breast
and liver cancer cells to doxorubicin-induced apoptosis.
Additionally, we tested whether transient knockdown of
FOXM1 results in increased apoptosis following DNA-damage.
To attain sufficient transient knockdown of FOXM1 we utilized
small interfering RNAs (siRNAs) against FOXM1. MIA PaCa-2
pancreatic (Fig. 1E) and MDA-MB-231 breast (Fig. 1F) control
and FOXM1 knockdown cancer cells were treated with various
concentrations of doxorubicin. We found that cells with transient
FOXM1 knockdown were more susceptible to apoptosis after
DNA-damage as detected by immunoblotting for cleaved caspase-
3, further supporting the idea that FOXM1 might play a role in
DNA-damage-induced apoptosis.
In order to confirm this effect, MIA PaCa-2 and MDA-MB-231
vector control and FOXM1 knockdown cells were subjected to
ionizing radiation. c-irradiation also induced robust apoptosis as
detected by the cleavage of caspase-3 in FOXM1 knockdown cells
(Fig. 2A, B). In addition, to quantitatively assess the degree of cell
FOXM1 and DNA-Damage-Induced Apoptosis
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31761Figure 1. Suppression of FOXM1 by RNAi sensitizes human cancer cells to doxorubicin. (A) HCT 116 p53 proficient and deficient human
colon cancer cells with FOXM1 knockdown were treated with doxorubicin (Doxo) as indicated. Immunoblotting for FOXM1, p53, cleaved caspase-3,
PARP and b-actin as the loading control was carried out 24 hours after treatment. (B) MIA PaCa-2 vector control and FOXM1 knockdown pancreatic
cancer cells were treated with the indicated concentrations of doxorubicin. Twenty-four hours after treatment cell lysates were immunoblotted for
FOXM1, cleaved caspase-3, PARP and b-actin as the loading control. (C) MDA-MB-231 vector control and FOXM1 knockdown breast cancer cells were
treated with doxorubicin as indicated. Immunoblot analysis was performed for FOXM1, cleaved caspase-3 and b-actin as the loading control 48 hours
after treatment. (D) Hep3B vector control and FOXM1 knockdown liver cancer cells were treated with the indicated concentrations of doxorubicin.
Cell lysates were immunoblotted for FOXM1, cleaved caspase-3 and b-actin as the loading control 24 hours after treatment. (E) Pancreatic cancer cells
MIA PaCa-2 were transfected with control and FOXM1 siRNA for 48 hours, and then treated as indicated. Twenty-four hours after treatment
immunoblotting was carried out with FOXM1, cleaved caspase-3 and b-actin antibodies. (F) Breast cancer cells MDA-MB-231 were transfected with
control and FOXM1 siRNA for 48 hours, then treated with the indicated concentrations of doxorubicin. Forty-eight hours after treatment cell lysates
were immunoblotted for FOXM1, cleaved caspase-3 and b-actin as the loading control.
doi:10.1371/journal.pone.0031761.g001
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vector control and FOXM1 knockdown cells were c-irradiated
with different doses, harvested and stained with propidium iodide.
The extent of apoptosis was measured by flow cytometry (Fig. 2C,
D). Both pancreatic and breast FOXM1 knockdown cells
exhibited significant increase in cell death following treatment
compared to the irradiated control counterparts. Altogether, these
data suggest that suppressing FOXM1 in human cancer cells could
make them more susceptible to cell death induced by DNA-
damaging agents.
Treatment with proteasome inhibitors sensitizes human
cancer cells to apoptosis induced by DNA-damage
Our group has reported previously that thiazole antibiotics
thiostrepton and Siomycin A are potent inhibitors of FOXM1
[25–28] and act as proteasome inhibitors [29]. Furthermore, we
have demonstrated that well-known proteasome inhibitors such as
bortezomib (velcade) and MG132 also target FOXM1 [29].
Downregulation of FOXM1 is one of the means, by which
proteasome inhibitors may induce cell death in vitro and in vivo
[27,29,41], but there are of course several potential FOXM1-
independent mechanisms of proteasome inhibitor-induced cell
death that we are not discussing in this study. To test FOXM1/
proteasome inhibitors together with DNA-damaging agents, MIA
PaCa-2 pancreatic cancer cell line was treated with the
combination of doxorubicin and bortezomib (Bor) (Fig. 3A) or
thiostrepton (Thio) (Fig. 3B), respectively. We found that inhibitors
of FOXM1, thiostrepton and bortezomib suppressed FOXM1
expression (data not shown) [27,29] and in combination with
doxorubicin exhibited stronger cleavage of caspase-3 or PARP
Figure 2. Suppression of FOXM1 by RNAi sensitizes human cancer cells to irradiation. (A) MIA PaCa-2 control and FOXM1 knockdown
pancreatic cancer cells were c-irradiated with 8 and 10 Gy. Seventy-two hours after irradiation cells were harvested and immunoblotting was carried
out with antibodies for FOXM1 and cleaved caspase-3. b-actin was used as the loading control. (B) MDA-MB-231 control and FOXM1 knockdown
breast cancer cells were subjected to c-irradiation with the indicated doses. Forty-eight hours following irradiation cells were harvested and
immunoblotting was performed for FOXM1, cleaved caspase-3 and b-actin as the loading control. (C–D) Degree of cell death was assessed by flow
cytometry following propidium iodide staining in MIA PaCa-2 pancreatic and MDA-MB-231 breast control and FOXM1 knockdown cancer cells,
respectively, 48 hours after c-irradiation. Graph shows quantification as a percentage of apoptotic cells compared to the vector control nontreated
cells, 6SD of a representative triplicate (C) or duplicate (D) experiment.
doi:10.1371/journal.pone.0031761.g002
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PaCa-2 pancreatic cancer cells were c-irradiated along with the treat-
ment of thiostrepton or bortezomib (Fig. 3C). Western blot analysis for
cleaved caspase-3 demonstrated that MIA PaCa-2 cells were more
sensitive to the combination of c-irradiation and thiostrepton or
bortezomib, respectively, than to individual drug treatment.
To further verify this effect, MDA-MB-231 breast and Hep3B
liver cancer cells were treated with doxorubicin (Fig. 3D, E) or
irradiated (Fig. 3F) in combination with thiostrepton or bortezo-
mib, respectively. Analysis of cleaved caspase-3 expression by
western blot revealed that the combination of DNA-damaging
agents with FOXM1/proteasome inhibitors led to increased
apoptosis in breast and liver cancer cells compared to treatment
with drugs alone. Since treatment with DNA-damaging agents in
conjunction with FOXM1/proteasome inhibitors induced such
marked apoptosis, the effect of their combination was also
examined on long-term survival by performing clonogenic assay.
MIA PaCa-2 and MDA-MB-231 human cancer cells were treated
with c-irradiation along with thiostrepton or bortezomib and the
colony forming ability was assessed 10 days later (Fig. 3G, H). We
found that the combination of c-irradiation and FOXM1/
proteasome inhibitors significantly inhibited colony formation
giving rise to much less number of colonies compared to individual
drug treatment. Taken together, these data suggest that the
combination of commonly used DNA-damaging chemotherapeu-
tic agents and FOXM1/proteasome inhibitors could be consid-
ered as a treatment strategy in order to improve therapeutic
response in various cancer treatments.
Sensitivity to DNA-damage after suppression of FOXM1 is
partially attributed to JNK activation and Bcl-2
downregulation
It is an intriguing fact that FOXM1, a known regulator of the
cell cycle, may inhibit DNA-damage-induced apoptosis. In order
to elucidate the possible underlying mechanism we turned to the
JNK signaling pathway, because it has been implicated in
responding to diverse stimuli including various apoptotic stimuli
[32]. It has been reported that c-irradiation leads to JNK
activation, which mediates radiation-induced apoptosis [33,42–
44]. To determine the effect of DNA-damage on the activation of
JNK in the presence or absence of FOXM1, MIA PaCa-2 vector
control and FOXM1 knockdown pancreatic cancer cells were c-
irradiated and immunoblotted for phospho-SAPK/JNK (Fig. 4A).
We observed that in FOXM1-knockdown cells the induction of
cell death following c-irradiation was accompanied by elevated
phosphorylation of JNK, suggesting that FOXM1 may inhibit the
activation of JNK in the presence of DNA-damage. In order to
investigate the potential role of JNK activation in apoptosis
induced by DNA-damage in FOXM1 knockdown cells, MIA
PaCa-2 pancreatic and MDA-MB-231 breast FOXM1 knock-
down cancer cells were c-irradiated in the presence of the specific
JNK inhibitor, SP600125 (Fig. 4B–E). Western blot analysis for
cleaved caspase-3 showed that induction of apoptosis by
irradiation was attenuated by treatment with the JNK inhibitor,
suggesting that JNK activation is partially responsible for the
programmed cell death following DNA-damage.
We also looked for additional mechanisms that might be
involved in the sensitization to DNA-damage in the absence of
FOXM1. The Bcl-2 family of proteins is one of the major
regulators of apoptosis [35–37]. Bcl-2 is best known to prevent
apoptosis by governing mitochondrial membrane integrity [35–
37]. Bcl-2 was also found to confer resistance to chemotherapeutic
agents and irradiation in various cell lines [35]. Immunoblot
analysis of Bcl-2 and Bcl-xL expression after c-irradiation revealed
that Bcl-2 was downregulated in FOXM1 knockdown pancreatic
and breast cancer cells (Fig. 4F, G), while Bcl-xL protein level
remained unchanged (Fig. 4F). To examine whether Bcl-2 is a
transcriptional target of FOXM1, Bcl-2 mRNA expression was
assessed by quantitative real-time (qRT)-PCR in vector control
and FOXM1 knockdown pancreatic and breast cancer cells.
FOXM1 knockdown led to 30–40% reduction in Bcl-2 mRNA
expression (Fig. 4H, I), suggesting that FOXM1 transcriptionally
up-regulates Bcl-2. Future experiments are needed to determine
whether Bcl-2 is a direct target of FOXM1. These data suggest
that suppression of FOXM1 might also sensitize human cancer
cells to DNA-damage via Bcl-2 downregulation.
In summary, we demonstrated that FOXM1 suppression by
stable or transient knockdown using RNAi (Fig. 1, 2) or by
treatment with FOXM1/proteasome inhibitors (Fig. 3) sensitizes
human cancer cells of different origin to apoptosis induced by
DNA-damaging agents including doxorubicin and c-irradiation.
The effect of endogenous FOXM1 knockdown in human cancer
cells on apoptosis after doxorubicin and c-irradiation treatment
has never been investigated before. JNK activation and Bcl-2
downregulation as a result of FOXM1 knockdown may explain
the resistance of FOXM1 proficient cells to apoptosis following
DNA-damage. Overall, our findings in accordance with previous
reports [11,14] confirm that targeting FOXM1 in combination
with DNA-damaging drugs or with c-irradiation could be a
valuable therapeutic approach against different types of human
cancer. Since some of the FOXM1/proteasome inhibitors such as
bortezomib are already in clinical practice, the data presented here
also suggest that the administration of commonly used DNA-
damaging chemotherapeutic agents in conjunction with FOXM1/
proteasome inhibitors or with other potential FOXM1 inhibitors
should be warranted serious consideration in order to improve
therapeutic outcome.
Figure 3. Combination of FOXM1/Proteasome inhibitors and DNA-damaging agents sensitizes human cancer cells to programmed
cell death. (A) Pancreatic cancer cells MIA PaCa-2 were treated with the indicated concentrations of doxorubicin and bortezomib (Bor) alone or in
combination. 24 hours after treatment cell lysates were analyzed by immunoblotting with cleaved caspase-3, PARP and b-actin antibodies. (B) MIA
PaCa-2 pancreatic cancer cells were treated with doxorubicin and thiostrepton (Thio) alone or in combination with the indicated concentrations for
24 hours. Immunoblotting was performed with antibodies specific for cleaved caspase-3 and b-actin as the loading control. (C) Pancreatic cancer cell
line MIA PaCa-2 was exposed to c-irradiation and treated in combination with thiostrepton or bortezomib for 24 hours. Immunoblotting was carried
out for cleaved caspase-3 and b-actin as the loading control. (D) MDA-MB-231 breast cancer cells were treated with doxorubicin in combination with
thiostrepton or bortezomib as indicated for 24 hours. Cell lysates were analyzed by immunoblotting with antibodies specific for cleaved caspase-3
and b-actin as the loading control. (E) Hep3B liver cancer cells were treated with doxorubicin and thiostrepton alone or in combination as indicated
for 24 hours. Immunoblotting was performed with antibodies specific for cleaved caspase-3 and b-actin as the loading control. (F) Breast cancer cell
line MDA-MB-231 was subjected to c-irradiation and treated in combination with thiostrepton or bortezomib for 24 hours. Immunoblot analysis was
performed with cleaved caspase-3 and b-actin antibodies. (G–H)1 610
5 MIA PaCa-2 (G) or MDA-MB-231 (H) human cancer cells were plated and
treated as indicated for 24 hours. 10 days after treatment cells were stained with crystal violet and representative plates are shown. Graph shows the
quantification 6SD of duplicate experiments (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0031761.g003
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Figure 4. FOXM1 modulates JNK activity and Bcl-2 expression to sensitize human cancer cells to DNA-damage. (A) MIA PaCa-2 control
and FOXM1 knockdown pancreatic cancer cells were c-irradiated with the indicated doses. Seventy-two hours following irradiation cells were
harvested and immunoblotting was carried out with antibodies specific for Phospho/Total-SAPK/JNK and cleaved caspase-3. b-actin was used as the
loading control. (B) MIA PaCa-2 FOXM1 knockdown pancreatic cancer cells were preincubated for 1 hour with 10 mM of JNK inhibitor, SP600125 and
then were c-irradiated as indicated. Forty-eight hours following irradiation cells were harvested and immunoblotting was performed for cleaved
caspase-3 and b-actin as the loading control. (C) The graphs show mean values 6 SEM of four independent experiments. (D) MDA-MB-231 FOXM1
knockdown breast cancer cells were preincubated for 1 hour with 10 mM of JNK inhibitor, SP600125 and then were subjected to c-irradiation with the
indicated doses. Seventy-two hours after irradiation cells were harvested and immunoblotting was performed with cleaved caspase-3 and b-actin
antibodies. (E) The graphs show mean values 6 SEM of two independent experiments. (F) Pancreatic MIA PaCa-2 control and FOXM1 knockdown
cancer cells were subjected to ionizing radiation with the indicated doses. Thirty-six hours following irradiation cells were harvested and
immunoblotting was carried out with antibodies specific for Bcl-2 and Bcl-xL. b-actin was used as the loading control. (G) Breast MDA-MB-231 control
and FOXM1 knockdown cancer cells were c-irradiated as indicated. Seventy-two hours following irradiation cells were harvested and immunoblotting
was performed for Bcl-2. b-actin was used as the loading control. (H) MIA PaCa-2 control and FOXM1 knockdown pancreatic cancer cells were
harvested for RNA extraction. Quantitative RT-PCR was carried out with Bcl-2 and cyclophilin primers. The graph demonstrates mean values 6SEM of
three independent experiments. (I) To extract RNA MDA-MB-231 control and FOXM1 knockdown breast cancer cells were harvested. Using Bcl-2 and
cyclophlin primers qRT-PCR was performed. The graph shows mean values 6SEM of three independent experiments.
doi:10.1371/journal.pone.0031761.g004
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